MA43404A - Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques - Google Patents

Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques

Info

Publication number
MA43404A
MA43404A MA043404A MA43404A MA43404A MA 43404 A MA43404 A MA 43404A MA 043404 A MA043404 A MA 043404A MA 43404 A MA43404 A MA 43404A MA 43404 A MA43404 A MA 43404A
Authority
MA
Morocco
Prior art keywords
expression
compositions
treatment
conditions
methods
Prior art date
Application number
MA043404A
Other languages
English (en)
Inventor
Amit N Patel
Dimki S Patel
Original Assignee
Intrexon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Corp filed Critical Intrexon Corp
Publication of MA43404A publication Critical patent/MA43404A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1738—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
MA043404A 2015-11-11 2016-11-11 Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques MA43404A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562254139P 2015-11-11 2015-11-11

Publications (1)

Publication Number Publication Date
MA43404A true MA43404A (fr) 2018-10-17

Family

ID=57543150

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043404A MA43404A (fr) 2015-11-11 2016-11-11 Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques

Country Status (14)

Country Link
US (3) US11154622B2 (fr)
EP (1) EP3387010A1 (fr)
JP (1) JP6976244B2 (fr)
KR (1) KR20180069081A (fr)
CN (1) CN108713025A (fr)
AU (1) AU2016353342B2 (fr)
BR (1) BR112018009645A2 (fr)
CA (1) CA3004742A1 (fr)
HK (1) HK1259137A1 (fr)
MA (1) MA43404A (fr)
MX (1) MX2018005886A (fr)
RU (1) RU2758489C2 (fr)
SG (1) SG11201803934YA (fr)
WO (1) WO2017083750A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641063B (zh) 2016-04-20 2022-11-15 能源环境和技术研究中心O.A., M.P. 用于增强pklr的基因表达的组合物和方法
CA3049652A1 (fr) 2017-01-10 2018-07-19 Intrexon Corporation Modulation de l'expression de polypeptides par l'intermediaire de nouveaux systemes d'expression de commutateurs geniques
KR102712841B1 (ko) * 2017-09-29 2024-10-04 (주)벳바젠 심부전의 예방 또는 치료용 약학적 조성물
CN111163810B (zh) 2017-10-16 2024-09-10 能源环境和技术研究中心O.A.,M.P. 用于递送pklr以治疗丙酮酸激酶缺乏症的慢病毒载体
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
JP7581048B2 (ja) 2018-03-06 2024-11-12 プレシゲン，インコーポレイテッド ヒトパピローマウイルスワクチンおよびその使用
SG11202008400SA (en) 2018-04-11 2020-09-29 Rocket Pharmaceuticals Ltd Compositions and methods for stem cell transplant
CA3096293A1 (fr) 2018-04-27 2019-10-31 Rocket Pharmaceuticals, Ltd. Therapie genique contre la degenerescence du systeme nerveux central (snc)
CA3100070A1 (fr) * 2018-05-18 2019-11-21 Universite Laval Vecteurs pour l'immunisation par adn
CA3100974A1 (fr) * 2018-05-25 2020-11-28 The Wistar Institute Neo-antigenes specifiques d'une tumeur et leurs methodes d'utilisation
AU2019354395A1 (en) 2018-10-01 2021-05-06 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors
KR20210070330A (ko) 2018-10-01 2021-06-14 아디셋 바이오, 인크. 혈액 종양의 치료를 위한 조작된 및 비-조작된 γδ-T 세포에 관한 조성물 및 방법
CN113710282A (zh) * 2019-03-29 2021-11-26 阿比奥梅德公司 用于生物剂治疗或载体化基因治疗中的左心室去负荷的系统和方法
SG11202110607WA (en) 2019-04-01 2021-10-28 Tenaya Therapeutics Inc Adeno-associated virus with engineered capsid
EP3814506A4 (fr) * 2019-05-21 2022-04-20 Université Laval Compositions immunogènes du virus de la fièvre hémorragique de crimée-congo
CN114173863A (zh) * 2019-08-07 2022-03-11 西北大学 用于在心脏中基因递送的材料和方法
US20220389452A1 (en) * 2019-09-20 2022-12-08 Ucl Business Ltd Gene therapy composition and treatment of right ventricular arrythmogenic cardiomyopathy
BR112022021134A2 (pt) 2020-04-20 2023-02-14 Tenaya Therapeutics Inc Vírus adeno-associado com capsídeo projetado
CA3185267A1 (fr) * 2020-08-07 2022-02-10 Spacecraft Seven, Llc Therapie genique destinee a plakophiline-2 (pkp2) faisant intervenir un vecteur de vaa
CN115698304A (zh) 2020-10-09 2023-02-03 特纳亚治疗股份有限公司 亲斑蛋白-2基因疗法的方法和组合物
US11781156B2 (en) * 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
CA3228581A1 (fr) * 2021-08-12 2023-02-16 Arthur M. Feldman Administration retrograde veineuse ou sinusale coronaire d'agents therapeutiques
WO2023232984A1 (fr) * 2022-06-02 2023-12-07 Patrick Most Protéine s100a1 destinée à être utilisée dans le traitement et la prévention d'une prolongation d'infarctus

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4985461A (en) 1985-10-21 1991-01-15 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US5117057A (en) 1985-10-21 1992-05-26 Rohm And Haas Company Insecticidal N' substituted-N-N'-disubstituted-hydrazines
US5225443A (en) 1986-05-01 1993-07-06 Rohm And Haas Company Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
IL100643A (en) 1991-01-25 1996-10-31 Nippon Kayaku Kk History of hydrazine and pesticides containing these histories as an active ingredient
US6013836A (en) 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
US5530028A (en) 1992-11-23 1996-06-25 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
AU2001249315A1 (en) 2000-03-22 2001-10-03 Rheogene, Inc. Ecdysone receptor-based inducible gene expression system
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
JP4328094B2 (ja) 2001-02-20 2009-09-09 イントレクソン・コーポレイション 新規置換突然変異体受容体および核受容体−ベースの誘導性遺伝子発現システムにおけるその使用
WO2002066614A2 (fr) 2001-02-20 2002-08-29 Rheogene Holdings, Inc. Recepteurs x de retinoides chimeriques et utilisations de ceux-ci dans un nouveau systeme d'expression de gene inductible fonde sur un recepteur d'ecdysone
US9493540B2 (en) 2001-02-20 2016-11-15 Intrexon Corporation Ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system
DK1534738T3 (da) 2001-02-20 2012-10-01 Intrexon Corp Nye substitutionsmutantreceptorer og anvendelse heraf i et inducérbart genekpressionssystem på basis af en nuklear receptor
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
EP1436394A4 (fr) 2001-09-26 2004-12-29 Rheo Gene Holdings Inc Acides nucleiques du recepteur a l'ecdysone de la cicadelle, polypeptides, et utilisation de ceux-ci
JP2005507247A (ja) 2001-09-26 2005-03-17 レオジーン・ホールディングス，インコーポレーテッド コナジラミエクジソン受容体核酸、ポリペプチド、およびそれらの使用
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7304162B2 (en) 2003-02-21 2007-12-04 Intrexon Corporation Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US9034650B2 (en) 2005-02-02 2015-05-19 Intrexon Corporation Site-specific serine recombinases and methods of their use
DK2043662T3 (en) 2006-07-26 2015-12-14 Intrexon Corp METHODS AND COMPOSITIONS FOR DISEASE TREATMENT
US7719424B2 (en) 2007-01-19 2010-05-18 Igt Table monitoring identification system, wager tagging and felt coordinate mapping
NZ582013A (en) 2007-05-29 2012-03-30 Intrexon Corp Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
KR101666228B1 (ko) * 2007-09-28 2016-10-13 인트렉손 코포레이션 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
KR101932027B1 (ko) 2007-10-08 2018-12-24 인트렉손 코포레이션 가공된 수지상 세포 및 암의 치료를 위한 이의 용도
US8236527B2 (en) * 2008-03-14 2012-08-07 Humanzyme Limited Recombinant production of authentic human proteins using human cell expression systems
WO2010042189A2 (fr) 2008-10-08 2010-04-15 Intrexon Corporation Cellules modifiées exprimant des immuno-modulateurs multiples et leurs utilisations
CN102740894B (zh) 2009-08-28 2015-07-15 克利夫兰临床医学基金会 用于治疗缺血组织的sdf-1递送
CN103038343A (zh) 2010-03-23 2013-04-10 英特瑞克斯顿股份有限公司 条件表达治疗蛋白的载体，包含所述载体的宿主细胞，及其应用
WO2012122025A2 (fr) 2011-03-04 2012-09-13 Intrexon Corporation Vecteurs exprimant une protéine de façon conditionnelle
MX382968B (es) * 2012-11-16 2025-03-12 United Biomedical Inc Vacuna de emergencia basada en péptidos sintéticos contra la fiebre aftosa.
WO2014089121A2 (fr) * 2012-12-03 2014-06-12 Thomas Ichim Administration rétrograde de cellules et d'acides nucléiques pour le traitement de maladies cardiovasculaires
WO2014145199A2 (fr) 2013-03-15 2014-09-18 The Cleveland Clinic Foundation Administration rétrograde de sdf-1 pour le traitement d'un infarctus du myocarde
WO2016187585A1 (fr) 2015-05-20 2016-11-24 Viventia Bio Inc. Lieur désimmunisé et méthodes d'utilisation
CN105754990A (zh) * 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 一种pd-1/ctla-4双特异性抗体的制备方法及其应用

Also Published As

Publication number Publication date
HK1259137A1 (zh) 2019-11-29
CA3004742A1 (fr) 2017-05-18
US20240148908A1 (en) 2024-05-09
RU2758489C2 (ru) 2021-10-28
BR112018009645A2 (pt) 2018-11-13
AU2016353342B2 (en) 2021-04-01
KR20180069081A (ko) 2018-06-22
MX2018005886A (es) 2018-08-15
RU2018117674A3 (fr) 2020-04-20
SG11201803934YA (en) 2018-06-28
JP2018536405A (ja) 2018-12-13
JP6976244B2 (ja) 2021-12-08
WO2017083750A1 (fr) 2017-05-18
US20220072159A1 (en) 2022-03-10
CN108713025A (zh) 2018-10-26
US20180360992A1 (en) 2018-12-20
RU2018117674A (ru) 2019-12-13
EP3387010A1 (fr) 2018-10-17
AU2016353342A1 (en) 2018-05-24
US11154622B2 (en) 2021-10-26

Similar Documents

Publication Publication Date Title
MA43404A (fr) Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques
EP3755805A4 (fr) Compositions et méthodes de traitement d'une hypoacousie non associée à l'âge chez un sujet humain
EP3558313A4 (fr) Substances pour le traitement d'affections liées à la stéatose hépatique
EP3294212A4 (fr) Administration de médicament à partir d'hydrogels
IL264025A (en) Novel fatty acid-modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
EP3316862A4 (fr) Compositions de microvésicules dérivées d'une plante comestible pour l'administration d'arnmi et méthodes de traitement du cancer
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
EP3405215A4 (fr) Méthodes destinées au traitement de la maladie de danon et d'autres troubles liés à l'autophagie
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
EP3528852A4 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
MA52252A (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
EP3325080A4 (fr) Procédés pour l'administration améliorée de principes actifs à des tumeurs
EP3496662A4 (fr) Protéine dérivée de la soie pour le traitement d'une inflammation
EP3661485A4 (fr) Procédé de production d'exosomes thérapeutiques à partir de nanoélectroporation et autre transfection de cellule non endocytique
EP3358929A4 (fr) Procédés et appareils pour le traitement d'une matière agricole
EP3672587A4 (fr) Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques
EP3528820C0 (fr) Nouvelles formulations liposomales pegylées d'apeline pour le traitement de maladies liées au système cardiovasculaire
EP4275746A3 (fr) Vésicules extracellulaires issues de cellules de lignée ostéoblastique, à usage thérapeutique et diagnostique
EP3331526A4 (fr) Enzymes de dégradation de la nicotine pour le traitement d'une dépendance à la nicotine et d'un empoisonnement à la nicotine
EP3307069A4 (fr) Utilisation du telmisartan pour la prévention et le traitement de la maladie du greffon contre l'hôte et d'autres maladies auto-immunes et allo-immunes
EP3398605A4 (fr) Composition médicinale pour améliorer un pronostic après redémarrage du propre rythme cardiaque d'un patient
EP3694579A4 (fr) Administration automatisée à base clinique de substances de traitement à l'oreille interne
WO2016057658A8 (fr) Agonistes de ppar, composés, compositions pharmaceutiques et méthodes d'utilisation de ceux-ci
EP3344071A4 (fr) Compositions combinées pour réguler des niveaux de glycémie, l'hépatoprotection, et pour la prévention et le traitement d'états médicaux associés